These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 34298783)
1. Clinical and Imaging Features of Non-Small Cell Lung Cancer with G12C KRAS Mutation. Wu MY; Zhang EW; Strickland MR; Mendoza DP; Lipkin L; Lennerz JK; Gainor JF; Heist RS; Digumarthy SR Cancers (Basel); 2021 Jul; 13(14):. PubMed ID: 34298783 [TBL] [Abstract][Full Text] [Related]
2. Efficacy of immunotherapy in patients with oncogene-driven non-small-cell lung cancer: a systematic review and meta-analysis. Chen J; Lu W; Chen M; Cai Z; Zhan P; Liu X; Zhu S; Ye M; Lv T; Lv J; Song Y; Wang D Ther Adv Med Oncol; 2024; 16():17588359231225036. PubMed ID: 38420602 [TBL] [Abstract][Full Text] [Related]
3. Real world outcomes in KRAS G12C mutation positive non-small cell lung cancer. Cui W; Franchini F; Alexander M; Officer A; Wong HL; IJzerman M; Desai J; Solomon BJ Lung Cancer; 2020 Aug; 146():310-317. PubMed ID: 32619782 [TBL] [Abstract][Full Text] [Related]
4. Imaging Features and Patterns of Metastasis in Non-Small Cell Lung Cancer with Digumarthy SR; Mendoza DP; Lin JJ; Rooney M; Do A; Chin E; Yeap BY; Shaw AT; Gainor JF Cancers (Basel); 2020 Mar; 12(3):. PubMed ID: 32183422 [TBL] [Abstract][Full Text] [Related]
7. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Fiala O; Pesek M; Finek J; Benesova L; Belsanova B; Minarik M Cancer Genet; 2013; 206(1-2):26-31. PubMed ID: 23313110 [TBL] [Abstract][Full Text] [Related]
8. Computed Tomography Imaging Features and Distribution of Metastases in ROS1-rearranged Non-Small-cell Lung Cancer. Digumarthy SR; Mendoza DP; Lin JJ; Chen T; Rooney MM; Chin E; Sequist LV; Lennerz JK; Gainor JF; Shaw AT Clin Lung Cancer; 2020 Mar; 21(2):153-159.e3. PubMed ID: 31708389 [TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics and prognostic value of the Liu SY; Sun H; Zhou JY; Jie GL; Xie Z; Shao Y; Zhang X; Ye JY; Chen CX; Zhang XC; Zhou Q; Yang JJ; Wu YL Biomark Res; 2020; 8():22. PubMed ID: 32607238 [TBL] [Abstract][Full Text] [Related]
10. KRAS mutated Non-Small Lung Carcinoma: A Real World Context from the Indian subcontinent. Batra U; Nathany S; Sharma M; Bp A; Jose JT; Singh H; Mattoo S; Mehta A Cancer Med; 2023 Feb; 12(3):2869-2874. PubMed ID: 36069080 [TBL] [Abstract][Full Text] [Related]
11. Correlation of KRAS G12C Mutation and High PD-L1 Expression with Clinical Outcome in NSCLC Patients Treated with Anti-PD1 Immunotherapy. Cefalì M; Epistolio S; Ramelli G; Mangan D; Molinari F; Martin V; Freguia S; Mazzucchelli L; Froesch P; Frattini M; Wannesson L J Clin Med; 2022 Mar; 11(6):. PubMed ID: 35329953 [TBL] [Abstract][Full Text] [Related]
12. Unique Profile of Driver Gene Mutations in Patients With Non-Small-Cell Lung Cancer in Qujing City, Yunnan Province, Southwest China. Zhou Y; Ge F; Du Y; Li Q; Cai J; Liu X; Guo Y; Shen Z; Duan L; Huang Z; Yao F; Zhu C; Shi H; Huang Y Front Oncol; 2021; 11():644895. PubMed ID: 33928034 [TBL] [Abstract][Full Text] [Related]
13. The Prevalence and Concurrent Pathogenic Mutations of Liu Y; Li H; Zhu J; Zhang Y; Liu X; Li R; Zhang Q; Cheng Y Cancer Manag Res; 2021; 13():2447-2454. PubMed ID: 33758543 [TBL] [Abstract][Full Text] [Related]
14. KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). Sebastian M; Eberhardt WEE; Hoffknecht P; Metzenmacher M; Wehler T; Kokowski K; Alt J; Schütte W; Büttner R; Heukamp LC; Stenzinger A; Jänicke M; Fleitz A; Zacharias S; Dille S; Hipper A; Sandberg M; Weichert W; Groschek M; von der Heyde E; Rauh J; Dechow T; Thomas M; Griesinger F; Lung Cancer; 2021 Apr; 154():51-61. PubMed ID: 33611226 [TBL] [Abstract][Full Text] [Related]
15. Outcomes and prognostic contributors in patients with Burns EA; Ensor JE; Hsu J; Thomas JS; Olsen RJ; Bernicker EH J Thorac Dis; 2021 Aug; 13(8):4785-4796. PubMed ID: 34527319 [TBL] [Abstract][Full Text] [Related]
16. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF. Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879 [TBL] [Abstract][Full Text] [Related]
17. Targeting oncogenic Yang L; Li Z; Binzel DW; Guo P; Williams TM Mol Ther Nucleic Acids; 2023 Sep; 33():559-571. PubMed ID: 37637206 [No Abstract] [Full Text] [Related]
18. Computed Tomography Imaging Characteristics of Non-Small-Cell Lung Cancer With Anaplastic Lymphoma Kinase Rearrangements: A Systematic Review and Meta-Analysis. Mendoza DP; Stowell J; Muzikansky A; Shepard JO; Shaw AT; Digumarthy SR Clin Lung Cancer; 2019 Sep; 20(5):339-349. PubMed ID: 31164317 [TBL] [Abstract][Full Text] [Related]
19. Prognostic Characteristics and Immunotherapy Response of Patients With Nonsquamous NSCLC With Wu SG; Liao WY; Su KY; Yu SL; Huang YL; Yu CJ; Chih-Hsin Yang J; Shih JY JTO Clin Res Rep; 2021 Feb; 2(2):100140. PubMed ID: 34589991 [TBL] [Abstract][Full Text] [Related]